
Rx Rundown: Novo Nordisk, Merck, Eli Lilly and more
Deals: Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term payments, if the latter meets certain development goals. Lexicon is eligible to earn up to $1 billion from later R&D, …